Nanobiotix (5NRA) AI Stock Analysis

0 Followers

Nanobiotix

(Frankfurt:5NRA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical validationThe melanoma study provides meaningful clinical validation for NBTXR3 in a heavily pre-treated, anti-PD-1-resistant population. Reported responses, disease control, safety, and survival signals support progression into randomized trials and could strengthen the platform’s partnering and commercialization prospects.

Negative Factors

Persistent unprofitabilityThe recent revenue rebound has not translated into sustainable profitability. Recurring EBIT, EBITDA, and net losses indicate that Nanobiotix still needs substantial development investment before its business model can support itself through earnings, leaving results sensitive to funding and partnering outcomes.

Nanobiotix (5NRA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.64B
Dividend Yield: ―
Average Volume (3M): 45
Price to Earnings (P/E): -26.4
Beta (1Y): 0.01
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 97
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Nanobiotix Business Overview & Revenue Model

Company Description

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanopartic...

Nanobiotix Earnings Call Summary

Earnings Call Date:Mar 31, 2026(Q4-2025)|% Change Since:8.46%|Next Earnings Date:May 18, 2022

Earnings Call SentimentPositive

Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.

Positive Updates

Strengthened balance sheet and extended cash runway

Cash and cash equivalents of EUR 52.8M as of 31-Dec-2025 (up from EUR 49.7M), nondilutive royalty financing agreement for up to $71M with Healthcare Royalty Partners, and management guidance that current cash plus expected financing should fund operations into early 2028 (contingent on receipt of remaining $21M expected in Q4 2026).

Negative Updates

Revenue driven by one-off accounting effect

FY2025 top-line benefit (EUR 32.6M) largely reflects a nonrecurring EUR 21.8M purchase-price accounting adjustment tied to the Janssen agreement amendment; this is a technical, nonrecurring effect and not indicative of recurring commercial revenue.

Company Guidance

Management guided that Nanobiotix is financially strengthened with EUR 52.8m cash as of 31‑Dec‑2025 (vs EUR 49.7m at 2024 YE) and a nondilutive royalty facility of up to $71m (with the remaining $21m expected in Q4‑2026), which together support a cash runway into early 2028 (excluding potential milestone inflows). 2025 financials included positive revenue of EUR 32.6m (reflecting a nonrecurring EUR 21.8m accounting impact from the March‑2025 Janssen amendment) versus negative EUR 7.2m in 2024; R&D fell to EUR 23.1m (‑43% y/y from EUR 40.5m), SG&A was EUR 20.4m (flat vs EUR 20.5m), and net loss narrowed to EUR 24.0m (EUR 0.50/share), a 65% improvement from EUR 68.1m (EUR 1.44/share). Operational milestones cited: Phase III NANORAY‑312 (head & neck) readout in H1‑2027, CONVERGE randomized Phase II in unresectable Stage III NSCLC (n≈120, 1:1:1) readout beginning 2027, four additional clinical readouts in 2026 (three completed), MD Anderson updates (summer timing possible), Curadigm IND/CMC progress and further preclinical/partner MTA activity, and the potential for Janssen milestone payments “in the hundreds of millions of euros” over the next 24–36 months.

Nanobiotix Risk Analysis

Nanobiotix disclosed 72 risk factors in its most recent earnings report. Nanobiotix reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Because of the significance of our license agreement with Janssen, we face a heightened risk with respect to our reliance in connection with the development and commercialization of NBTXR3.Q4, 2023

Nanobiotix Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5NRA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEPN	56Neutral	$2.49B	-37.64	-14.98%	―	336.69%	14.29%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZBIO	51Neutral	$1.94B	-2.85	-208.91%	―	-26.67%	-121.60%
BCAX	45Neutral	$675.82M	-3.03	-49.13%	―	―	-55.27%
UPB	42Neutral	$185.13M	-1.06	-57.09%	―	2.54%	-31.89%

* Healthcare Sector Average

Performance Comparison

DE:5NRA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5NRA	Nanobiotix Sa ADR	28.20	10.30	57.54%
BCAX	Bicara Therapeutics Inc.	10.53	-3.73	-26.16%
ZBIO	Zenas BioPharma, Inc.	28.70	-6.96	-19.52%
UPB	Upstream Bio, Inc.	3.20	-20.14	-86.29%
SEPN	Septerna, Inc.	48.56	29.32	152.39%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nanobiotix AI Stock Analysis